Research ExplorerPublicationsPrognostic significance of cytogenetic heterogeneity in pati...

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

Standard

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. / Merz, Maximilian; Jauch, Anna; Hielscher, Thomas; Bochtler, Tilmann; Schönland, Stefan Olaf; Seckinger, Anja; Hose, Dirk; Bertsch, Uta; Neben, Kai; Raab, Marc Steffen; Hillengass, Jens; Salwender, Hans; Blau, Igor Wolfgang; Lindemann, Hans-Walter; Schmidt-Wolf, Ingo G H; Scheid, Christof; Haenel, Mathias; Weisel, Katja C; Goldschmidt, Hartmut.

In: BLOOD ADV, Vol. 2, No. 1, 09.01.2018, p. 1-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Merz, M, Jauch, A, Hielscher, T, Bochtler, T, Schönland, SO, Seckinger, A, Hose, D, Bertsch, U, Neben, K, Raab, MS, Hillengass, J, Salwender, H, Blau, IW, Lindemann, H-W, Schmidt-Wolf, IGH, Scheid, C, Haenel, M, Weisel, KC & Goldschmidt, H 2018, 'Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma', BLOOD ADV, vol. 2, no. 1, pp. 1-9. https://doi.org/10.1182/bloodadvances.2017013334

APA

Merz, M., Jauch, A., Hielscher, T., Bochtler, T., Schönland, S. O., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Hillengass, J., Salwender, H., Blau, I. W., Lindemann, H-W., Schmidt-Wolf, I. G. H., Scheid, C., Haenel, M., Weisel, K. C., & Goldschmidt, H. (2018). Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. BLOOD ADV, 2(1), 1-9. https://doi.org/10.1182/bloodadvances.2017013334

Vancouver

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. BLOOD ADV. 2018 Jan 9;2(1):1-9. https://doi.org/10.1182/bloodadvances.2017013334

Bibtex

@article{b56ac0216c784560b643079bcfcafe9b,
title = "Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma",
abstract = "We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11;14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is of major prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.",
keywords = "Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Chromosome Aberrations, Humans, In Situ Hybridization, Fluorescence, Middle Aged, Multiple Myeloma, Netherlands, Prognosis, Transplantation, Autologous, Young Adult, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "Maximilian Merz and Anna Jauch and Thomas Hielscher and Tilmann Bochtler and Sch{\"o}nland, {Stefan Olaf} and Anja Seckinger and Dirk Hose and Uta Bertsch and Kai Neben and Raab, {Marc Steffen} and Jens Hillengass and Hans Salwender and Blau, {Igor Wolfgang} and Hans-Walter Lindemann and Schmidt-Wolf, {Ingo G H} and Christof Scheid and Mathias Haenel and Weisel, {Katja C} and Hartmut Goldschmidt",
year = "2018",
month = jan,
day = "9",
doi = "10.1182/bloodadvances.2017013334",
language = "English",
volume = "2",
pages = "1--9",
journal = "BLOOD ADV",
issn = "2473-9529",
publisher = "Elsevier BV",
number = "1",

}

RIS

TY - JOUR

T1 - Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

AU - Merz, Maximilian

AU - Jauch, Anna

AU - Hielscher, Thomas

AU - Bochtler, Tilmann

AU - Schönland, Stefan Olaf

AU - Seckinger, Anja

AU - Hose, Dirk

AU - Bertsch, Uta

AU - Neben, Kai

AU - Raab, Marc Steffen

AU - Hillengass, Jens

AU - Salwender, Hans

AU - Blau, Igor Wolfgang

AU - Lindemann, Hans-Walter

AU - Schmidt-Wolf, Ingo G H

AU - Scheid, Christof

AU - Haenel, Mathias

AU - Weisel, Katja C

AU - Goldschmidt, Hartmut

PY - 2018/1/9

Y1 - 2018/1/9

N2 - We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11;14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is of major prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.

AB - We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11;14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is of major prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.

KW - Adolescent

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bortezomib

KW - Chromosome Aberrations

KW - Humans

KW - In Situ Hybridization, Fluorescence

KW - Middle Aged

KW - Multiple Myeloma

KW - Netherlands

KW - Prognosis

KW - Transplantation, Autologous

KW - Young Adult

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1182/bloodadvances.2017013334

DO - 10.1182/bloodadvances.2017013334

M3 - SCORING: Journal article

C2 - 29344579

VL - 2

SP - 1

EP - 9

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 1

ER -